Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

CAR-T Cells in Treating Patients With Relapsed or Refractory NHL

Early Phase 1

Conditions: Refractory Indolent Adult Non-Hodgkin Lymphoma

Interventions: Drug: CD19 CAR-T
Drug: CD22 CAR-T
Drug: CD19+CD22 CAR-T
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2020-11-13

Last Posted Date: 2020-11-13

Lead Sponsor: Hebei Senlang Biotechnology Inc., Ltd.

Target Recruit Count: 100

Registration Number: NCT04626739

Locations: 🇨🇳
No.2 Hospital of Hebei Medical University, Shijiazhuang, Hebei, China

CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

Early Phase 1

Conditions: Relapsed or Refractory Multiple Myeloma

Interventions: Drug: BCMA CAR-T
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2020-11-13

Last Posted Date: 2020-11-13

Lead Sponsor: Hebei Senlang Biotechnology Inc., Ltd.

Target Recruit Count: 50

Registration Number: NCT04626752

Locations: 🇨🇳
the Second Hospital of HeBei Medical University (HBMU), Shijiazhuang, Hebei, China

FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

Phase 1

Recruiting

Conditions: Rhabdomyosarcoma

Interventions: Radiation: radiotherapy
Drug: Irinotecan
Drug: Vinorelbine
Drug: Actinomycin D
Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Ifosfamide
Drug: Temozolomide
Drug: Regorafenib
Drug: Vincristine

First Posted Date: 2020-11-12

Last Posted Date: 2024-05-23

Lead Sponsor: University of Birmingham

Target Recruit Count: 1672

Registration Number: NCT04625907

Locations: 🇬🇷
University Unit of Pediatric Oncology-hematology - Children's Hospital Agia Sophia, Athens, Greece
🇮🇱
Rambam Health Care Campus, Haifa, Israel
🇮🇱
Hadassah University Medical Centre, Jerusalem, Israel

and more 125 locations

FT538 in Subjects With Advanced Hematologic Malignancies

Phase 1

Terminated

Conditions: AML, Adult
Acute Myeloid Leukemia
Multiple Myeloma
Myeloma

Interventions: Drug: FT538
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Daratumumab
Drug: Elotuzumab

First Posted Date: 2020-11-04

Last Posted Date: 2023-09-21

Lead Sponsor: Fate Therapeutics

Target Recruit Count: 42

Registration Number: NCT04614636

Locations: 🇺🇸
Washington University, Saint Louis, Missouri, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

and more 5 locations

Comparison of BTD and BCD Based Regimens in the Treatment of AL Amyloidosis

Phase 4

Conditions: Immunoglobulin Light-Chain Amyloidosis

Interventions: Drug: Thalidomide
Drug: Cyclophosphamide

First Posted Date: 2020-11-03

Last Posted Date: 2020-11-03

Lead Sponsor: Guangdong Provincial People's Hospital

Target Recruit Count: 70

Registration Number: NCT04612582

Locations: 🇨🇳
Guangdong Provincial People'S Hospital, Guangzhou, Guangdong, China

T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer

Phase 1

Terminated

Conditions: Metastatic Ovarian Cancer
Metastatic Fallopian Tube Cancer
Peritoneal Cancer

Interventions: Drug: Cyclophosphamid
Drug: Ipilimumab
Drug: Fludarabine Phosphate
Biological: Tumor Infiltrating Lymphocytes infusion
Drug: Nivolumab
Drug: Relatlimab

First Posted Date: 2020-11-02

Last Posted Date: 2024-07-19

Lead Sponsor: Inge Marie Svane

Target Recruit Count: 5

Registration Number: NCT04611126

Locations: 🇩🇰
National Center for Cancer Immune Therapy (CCIT-DK), Herlev, Denmark

Axi-cel in CNS Lymphoma

Phase 1

Active, not recruiting

Conditions: Lymphoma Cns
Lymphoma

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Biological: Axicabtagene Ciloleucel

First Posted Date: 2020-10-29

Last Posted Date: 2024-06-25

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 18

Registration Number: NCT04608487

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy

Phase 1

Terminated

Conditions: Melanoma
Non-small Cell Lung Cancer
Renal Cell Carcinoma
Small-cell Lung Cancer
Cutaneous Squamous Cell Carcinoma
Squamous Cell Carcinoma of Head and Neck
Urothelial Carcinoma
Anal Squamous Cell Carcinoma
Merkel Cell Carcinoma

Interventions: Biological: GEN-011
Drug: IL-2
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2020-10-22

Last Posted Date: 2022-07-15

Lead Sponsor: Genocea Biosciences, Inc.

Target Recruit Count: 49

Registration Number: NCT04596033

Locations: 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 5 locations

A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients with DLBCL

Phase 2

Recruiting

Conditions: Lymphoma, B-Cell
DLBCL

Interventions: Drug: Polatuzumab vedotin
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Prednisone

First Posted Date: 2020-10-20

Last Posted Date: 2024-11-05

Lead Sponsor: University of Rochester

Target Recruit Count: 39

Registration Number: NCT04594798

Locations: 🇺🇸
University of Rochester, Rochester, New York, United States

A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer

Phase 1

Completed

Conditions: Triple-Negative Breast Cancer

Interventions: Drug: Tiragolumab
Drug: Atezolizumab
Drug: Nab-paclitaxel
Drug: Carboplatin
Drug: Doxorubicin
Drug: Granulocyte colony-stimulating factor (G-CSF)
Drug: Cyclophosphamide
Drug: Granulocyte-macrophage colony-stimulating factor (GM-CSF)

First Posted Date: 2020-10-12

Last Posted Date: 2023-03-15

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 83

Registration Number: NCT04584112

Locations: 🇺🇸
Tennessee Onc., PLLC - SCRI, Nashville, Tennessee, United States
🇦🇺
Mater Hospital; Cancer Services, South Brisbane, Queensland, Australia
🇧🇷
Hospital Sírio-Libanês, Sao Paulo, SP, Brazil

and more 21 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy